Research programme: monoclonal antibody therapeutics - Alethia BioTherapeutics
Alternative Names: AB-0440; AB-0447; AB-25E9; AB-3A4; AB-3A4-ADC; AB-3D3; AB-IsoG; Anti-KAAG1 monoclonal antibody - Alethia BioTherapeutics; Anti-Siglec-15 monoclonal antibody - Alethia BioTherapeuticsLatest Information Update: 04 Sep 2023
At a glance
- Originator Alethia BioTherapeutics
- Class Immunotoxins; Monoclonal antibodies
- Mechanism of Action Immunomodulators; Membrane protein inhibitors; Siglec-15 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bone resorption; Malignant melanoma; Ovarian cancer; Renal cancer; Triple negative breast cancer
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in Canada (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bone-resorption in Canada (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Ovarian-cancer in Canada (Parenteral)